Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 7:46 PM
Ignite Modification Date:
2025-12-25 @ 5:23 PM
NCT ID:
NCT03636503
Group ID:
EG001
Title:
Rituximab+Utomilumab+Avelumab-10mg
Description:
* Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only
* Utomilumab is administered intravenously over 1 hour once every 4 weeks
* Avelumab is administered intravenously over 1 hour once every 2 weeks, 10mg
Rituximab: Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatment
Utomilumab: Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
Avelumab: Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
-PF-04518600 is administered intravenously over 1 hour on day 1 and day 15, 0.3mg/kg
Deaths Number Affected:
1
Deaths Number At Risk:
None
Serious Number Affected:
0
Serious Number At Risk:
4
Other Number Affected:
3
Other Number At Risk:
4
Study:
NCT03636503
Results Section:
NCT03636503
Adverse Events Module:
NCT03636503